GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using...
GeoVax Labs (GOVX.US) closed regular hours down 5.5% at $1.19, driven by lingering pressure from last week's announcement of a $2.7 million net private placement and an $863,000 warrant exercise inducement, which weighed on pre-market sentiment. The stock opened weak, hit an intraday high of $1.27 before settling at the session low of $1.19, diverging from the pre-market peak of $1.295. Q1 2026 net loss of $5.29 million, cash of $1.3 million, and zero revenue kept fundamentals under scrutiny. However, the stock remains up 474.88% year-to-date and 933.88% above its 52-week low of $0.1151, though it now trades below the 20-day ($1.307) and 60-day ($1.525) moving averages, signaling waning short-term momentum. After-hours quotes edged up to $1.26, leaving direction unclear.
Geovax Labs Risk Profile Appears Stable, But Investors Should Watch for Emerging SEC-Disclosed Pressures
GeoVax Labs, Inc. 2026: Revenue $0 EPS ($0.97) — 10-Q Summary
GeoVax Labs | 8-K: FY2026 Q2 Revenue: USD 0
GeoVax Q2 FY26 net loss narrows to $4.43 million, or $0.97 a share; revenue posts no revenue
Pre-market hot trades in US stocks: GeoVax Labs up 10.76% in pre-market; Banco Santander SA-Spon up 3.90% in pre-market
GeoVax gets Nasdaq notice for failing $2.5 million stockholders’ equity requirement